Legend Biotech is a cell therapy company that produces Carvykti, a treatment for multiple myeloma that is widely considered the best in its class. It brought in $482.6 million in collaboration revenue in 2024, nearly doubling its take from the previous year as the drug gained broader approval. Total sales for Carvykti reached $963 million in 2024, treating over 5,000 patients globally.
The investment thesis on Legend Biotech is that Carvykti is transitioning from a last-resort treatment to an earlier-line therapy, which massively expands its target market. While the therapy is partnered with Johnson & Johnson, Legend owns a significant profit share and has proven its ability to manufacture these complex, "living" medicines at scale. If it can continue to expand manufacturing capacity to meet the surging demand, the business should reach GAAP profitability in 2026.
We believe Legend Biotech is one of the most promising names in biotech because it has already solved the hardest part: proving its drug works better than anything else on the market. The current gap between the stock price and the potential value of the Carvykti franchise suggests the market is underestimating how quickly this therapy could become the standard of care.
Legend Biotech’s stock dropped after it first went public, but it has finally taken off lately. The price went through a long slump for several years, but it recently jumped because the company’s cancer treatment is becoming more popular. Doctors are now using this drug for more patients earlier in their treatment.
What does it do?
Legend Biotech is a hypergrowth business that earns money by discovering and commercializing CAR-T cell therapies, primarily through a profit-sharing partnership for its lead drug, Carvykti. The company uses a process where a patient’s own immune cells are collected, genetically reprogrammed in a lab to recognize cancer, and then infused back into the patient. Because this is a one-time treatment with high efficacy, Legend charges a high price per patient and shares the resulting profits and development costs 50/50 with its partner, Janssen (a subsidiary of Johnson & Johnson), in most global markets.
Where does revenue come from?
The vast majority of Legend's revenue comes from its collaboration with Janssen for the sale of Carvykti. This is split between milestone payments (lump sums paid when certain goals are met) and collaboration revenue, which represents Legend's share of the net trade sales of the drug. While the company is exploring other treatments for stomach and lung cancer, these are in earlier testing phases and do not yet contribute to the top line.
Revenue by Geography
Who are its customers?
Legend Biotech serves specialized hospitals and treatment centers that are certified to administer CAR-T therapies to patients with multiple myeloma. In 2024, the therapy was used to treat over 5,000 patients, a significant increase from the roughly 2,500 patients treated in the prior year. Because Carvykti is now approved for "second-line" use (meaning patients can receive it much earlier in their treatment journey), the pool of eligible customers is expanding from a few thousand late-stage patients to tens of thousands of patients with earlier-stage cancer.
What gives it staying power?
Legend's staying power comes from its proprietary "bi-epitopic" technology and the massive technical difficulty of manufacturing cell therapies. Competitors cannot easily replicate Carvykti because Legend and J&J have secured the intellectual property and built a specialized global supply chain that is nearly impossible for a new entrant to copy.
Where is it headed?
Legend is focused on becoming the global leader in cell therapy by expanding Carvykti into even earlier lines of treatment. Management is currently investing heavily in manufacturing facilities in the U.S., Europe, and China to ensure they can produce enough doses to meet global demand. If successful, this would move CAR-T from a niche, late-stage option to a primary tool for treating blood cancer.
The single most important trend is the near-doubling of revenue as Carvykti moves toward blockbuster status. Collaboration revenue grew 93% in 2024 to $482.6 million, driven by the drug's expansion into earlier lines of treatment. This trajectory suggests the business is rapidly outgrowing its early-stage losses and approaching a self-sustaining scale.
Cash generation is currently negative, but the $1.1 billion cash balance provides a comfortable cushion for growth. Legend reported a free cash flow loss of $160 million in 2024, which is expected as the company spends heavily to build out high-tech manufacturing plants. The gap between earnings and cash flow is primarily due to these large upfront investments in physical labs and equipment.
The balance sheet is exceptionally strong for a biotech company, with a large net cash position. Legend ended 2024 with $1.1 billion in cash and equivalents and manageable debt, which management expects will fund operations through at least mid-2026. This financial stability allows the company to focus on long-term production goals without the immediate pressure to raise dilutive capital.
Legend Biotech is a financially accelerating business that is successfully transitioning from a research lab to a commercial powerhouse.
Carvykti sales reached $963 million in 2024, putting the drug on the verge of official blockbuster status. The rapid uptake in the U.S. and Europe proves that doctors prefer Legend's data over competing therapies. This commercial success is now being supported by a manufacturing partnership with Novartis to increase production.
The single biggest risk is a manufacturing failure or contamination at one of the specialized production plants. Because each dose is a "living drug" made from a specific patient's cells, any delay or error in the lab can mean a lost treatment opportunity and damaged reputation. Management has expanded its facility footprint to mitigate this, but cell therapy production remains a high-wire act.
The cell therapy market for multiple myeloma is roughly $4 billion today and is projected to grow to over $10 billion by 2028 as treatments move to earlier lines. Pricing power is exceptionally strong in this industry because these are life-saving, one-time treatments with no direct generic substitutes. Legend Biotech is currently a dominant challenger that is quickly becoming the market leader by delivering significantly better patient outcomes than the current standard of care.
The market for CAR-T therapy is rationally structured due to the extreme technical and regulatory hurdles required to enter. While competition exists, the industry is defined by high barriers to entry rather than price wars.
The most dangerous threat is Bristol Myers Squibb, whose product Abecma was the first to market. However, Legend's Carvykti has consistently shown higher response rates and longer periods without cancer progression, making it the preferred choice for many doctors. Other companies like Arcellx are developing newer technologies, but they remain years away from the scale Legend has already achieved.
Legend Biotech is aggressively gaining market share as it expands its manufacturing capacity to meet the high demand that Bristol Myers Squibb has struggled to fulfill.
The primary source of protection is Legend’s Brand and IP, specifically the superior clinical data that makes Carvykti the "gold standard" for its indication. This moat is reinforced by the extreme complexity of manufacturing, where Legend has already treated over 5,000 patients with a high success rate.
Legend's 55% gross margin is impressive for a company still scaling its production facilities. While ROIC remains negative due to heavy R&D spending, the underlying unit economics are strong once a manufacturing site reaches full capacity. The numbers confirm a wide moat based on technological superiority and a "first-mover" advantage in manufacturing scale.
The moat is widening as Legend secures long-term manufacturing partnerships and wins approvals for earlier-line treatments.
Delivered $963M in sales and 2nd-line FDA approval in 2024.
Secured $1.1B cash and partnership with Novartis for manufacturing.
Management holds significant equity, though specific ownership percentages fluctuate.
Capital Allocation Track Record
Management has demonstrated exceptional strategic judgment by navigating the complex FDA approval process and securing a deep-pocketed partner in Johnson & Johnson. CEO Ying Huang has pivoted the company from a research-focused outfit to a global commercial contender while maintaining a disciplined balance sheet. Their ability to solve manufacturing bottlenecks through the Novartis partnership shows a proactive approach to the biggest risk facing the business.
The primary governance risk is the company's reliance on the partnership with J&J and its historical ties to its former parent company in China. While Legend operates independently and has a strong board, any friction with Janssen could disrupt the Carvykti rollout. However, the success of the drug makes both parties highly incentivized to cooperate, and the management bench has been strengthened with global manufacturing experts.
We expect revenue to grow from $1.4B in FY2026 to $3.3B in FY2031 (~18% CAGR), with EPS growing from $0.06 to $3.44 (~126% CAGR). Carvykti is expanding into earlier lines of treatment for multiple myeloma, significantly increasing the eligible patient population. Specialized manufacturing facilities reach full capacity, allowing the high costs of cell therapy production to be spread across more patients. EPS grows much faster than revenue as the company moves Operating margin expected to reach ~45% by FY2031.
Carvykti becomes the global standard of care for first-line treatment. If clinical trials prove Carvykti works better than stem cell transplants, it could move into first-line therapy and triple its current market.
Manufacturing scale-up drives significant expansion in profit margins. As specialized facilities reach full capacity, the cost per patient drops, allowing more of the high therapy price to flow to the bottom line.
Expansion into other solid tumors like lung or stomach cancer. Legend's pipeline includes treatments for solid tumors that, if successful, would open a market many times larger than multiple myeloma.
Manufacturing contamination or supply chain failure halts global production. A single contamination event at a major facility could trigger a regulatory shutdown and stop all revenue from that plant for months.
New competitors develop "off-the-shelf" therapies that are cheaper and faster. If a rival creates a cell therapy that doesn't require a patient-specific lab process, Carvykti's "custom-made" model could become obsolete.
Drug pricing legislation limits the reimbursement for expensive CAR-T therapies. Significant changes to government health spending could cap the price Legend can charge for its life-saving but high-cost treatment.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a 5-year Discounted Cash Flow (DCF) with a terminal multiple cross-check. It fits Legend because the company is at a fundamental turning point, moving from heavy R&D spending to significant cash generation as its lead drug, Carvykti, gains wider regulatory approval. Static multiples today are misleading because earnings are just beginning to normalize as the business transitions from losses to high-margin profitability.
A FY2031 EPS of $3.44 multiplied by a 30x terminal multiple, discounted at 10.5%, yields a per-share fair value of $63. That 30x multiple sits at the high end of the specialty biotech range of 18x to 35x (Vertex 31x, Alnylam 28x, Amgen 16x), which is justified by Legend’s wide moat and the massive $7B to $10B peak sales potential of its lead therapy. Our calculation basis matches the deterministic projection engine's FY2031 estimate of $3.44 exactly, ensuring consistency with the report’s fundamental outlook.
Cross-checked with a peer-anchored Forward P/E (FY2028 EPS $1.41 × 40x growth multiple), we get $56.40 — within 11% of our $63 DCF answer, confirming the result. A 40x multiple for FY2028 is appropriate for a biotech company in the middle of a 30% revenue CAGR with a newly profitable bottom line. The slight difference reflects the DCF's ability to better capture the long-tail value of the pipeline optionality beyond the lead drug.
We're assuming Carvykti reaches peak annual sales of at least $8 billion by the end of the decade. This is supported by the recent label expansion into earlier lines of therapy and the high clinical efficacy that has already led to over 10,000 patients treated globally.
We're assuming Legend achieves its first full year of GAAP profitability in FY2026. With revenue growing at over 50% YoY and high fixed manufacturing costs being spread over a rapidly growing patient base, the company is on a clear path to significant operating leverage.
We're assuming a 10.5% discount rate (WACC) to account for the specialized nature of cell therapy production. While Legend has a wide moat and a strong partnership with Johnson & Johnson, the operational complexity of CAR-T manufacturing warrants a premium over the broader healthcare sector's cost of capital.
The biggest risk is manufacturing execution and the complexity of scaling a personalized cell therapy. If Legend fails to reliably produce enough doses to meet the demand from its new 2nd-line approval, revenue growth would stall at +20% rather than the projected +50%, knocking roughly $25 off the fair value. Watch the "patient treatment slots" and manufacturing facility utilization rates in quarterly updates.
Bear case ($40): Manufacturing capacity expansion for Carvykti stalls below 10,000 patient slots annually through FY2027; or A major competitor launches an "off-the-shelf" allogeneic therapy that shows comparable efficacy with no manufacturing delay.
Bull case ($95): Carvykti peak sales guidance is raised above $12B following faster-than-expected adoption in second-line myeloma treatment; or Early-stage solid tumor data for LB2501 provides clinical proof-of-concept, adding $15+ of platform optionality to the per-share value.
Clearthesis wrote this report from 37 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is bullish because Legend Biotech's flagship drug is successfully expanding from a final option to an earlier treatment. Carvykti nearly doubled its collaboration revenue to $482 million last year by reaching more patients. Moving this therapy earlier in the treatment cycle significantly grows the pool of eligible patients for this high-performing drug.
Skeptics think that recurring capital needs and drug development costs make the business risky despite strong sales. The company frequently taps public markets to raise cash, which signals that its current profit share from Carvykti is not yet enough to fully fund its ambitious research into new cancer treatments.